Home/Mallinckrodt Pharmaceuticals/Sigurdur (Siggi) Olafsson

S(

Sigurdur (Siggi) Olafsson

Former President and CEO

Mallinckrodt Pharmaceuticals

Therapeutic Areas

Autoimmune Diseases Rare Diseases Critical Care Central Nervous System Pain Management

Mallinckrodt Pharmaceuticals Pipeline

Drug	Indication	Phase
Terlipressin (TERLIVAZ®)	Hepatorenal Syndrome Type 1 (HRS-1)	Approved
Stannsoporfin (INH-001)	Prevention of severe hyperbilirubinemia in newborns	Phase 3
StrataGraft	Thermal Burns	Approved
H.P. Acthar® Gel	Multiple autoimmune/inflammatory conditions	Approved

Leadership Team at Mallinckrodt Pharmaceuticals

Bryan M. Reasons

Former Executive Vice President and CFO

Steven J. Romano, M.D.

Former Executive Vice President and Chief Scientific Officer

View full Mallinckrodt Pharmaceuticals profile